Van Tuyl Christopher 4

What Happened
Christopher Van Tuyl, Chief Legal Officer of Immunovant, was granted equity awards on April 7, 2026: 41,343 restricted stock units (RSUs) and 59,820 derivative awards (option-style grant), each recorded at $0.00 (no cash paid). These are compensation grants, not open-market purchases or sales, so they do not represent an immediate buy/sell of Immunovant stock.

Key Details

• Transaction date: 2026-04-07; Form 4 filed 2026-04-09 (timely filing). Accession: 0001764013-26-000036.
• Reported acquisition price: $0.00 for both grants (standard for RSU and option awards).
• Shares/units granted: 41,343 RSUs; 59,820 derivative/option-style awards.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes / vesting:
  • RSUs (41,343): vest 25% on April 1, 2027, then in 12 substantially equal quarterly installments thereafter, subject to continued service.
  • Options/derivative award (59,820): vest 25% on April 1, 2027, then in 36 substantially equal monthly installments thereafter, subject to continued service.
• No indication these were exercised or sold immediately; they are prospective compensation awards.

Context
RSUs give the holder a contingent right to receive shares upon vesting. The derivative/option-style award will require future vesting (and likely exercise) before the holder receives shares. Such grants are common as part of executive compensation and do not by themselves signal buying or selling intent in the market.